Biotech fundraising is increasingly resembling traditional paths seen in software, with many funds showing interest in innovative science companies.

There's a significant gap in funding for early-stage biotech discoveries, leading many companies to apply to Y Combinator when they have initial data suggesting a promising approach to curing diseases.

Successful biotech funds often incubate ideas internally before spinning them out as independent companies, which has proven effective in the industry.

Many biotech companies have raised significantly more capital through Y Combinator than they would have in traditional biotech venture settings, with over $200 million raised for these companies.

The biotech industry is experiencing a surge in startups due to unprecedented access to capital and advancements in therapeutic modalities.

We raised a later stage fund to support hard tech companies that need significant capital, as many investors are not willing to provide that.

There is a growing trend of former students starting biotech companies, which encourages others to explore similar entrepreneurial paths.

Investing in things that aren't software is okay if you believe in the founder's expertise; there are many great opportunities in biotech that could lead to significant exits.

The focus for biotech companies is on de-risking their technology by obtaining experimental data and developing a viable therapeutic intervention, which is crucial before entering clinical trials.